SHAWNEE, Kan. (April 28, 2008) — Baytril® 100 (enrofloxacin) Injectable Solution is now approved by the Food and Drug Administration (FDA) for use in swine. Baytril 100 is a powerful, fast-acting antimicrobial for treatment and control of swine respiratory disease (SRD). The lifesaving antimicrobial is bactericidal, killing all four major SRD-causing bacteria: Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis. Baytril 100 works fast and starts killing bacteria within a matter of minutes.1 Furthermore, Baytril 100 is concentration-dependent, not time-dependent, delivering peak therapeutic drug concentrations via a single, subcutaneous injection behind the ear. Now, for the first time, swine integrators, producers, and veterinarians will benefit from the unique technology of the fluoroquinolone class of antimicrobials. “The introduction of Baytril 100 into the swine market is important because it gives producers and veterinarians access to the unique mode of action of the fluoroquinolone class of antibiotics,” says Dr. Cary Christensen, Senior Director, Food Animal Products Business Unit at Bayer Animal Health. “We are very excited to bring the swine industry this new management tool to help improve herd health.” Baytril 100 has been the choice of bovine veterinarians and beef cattle producers for more than 10 years, since its introduction in 1998, and is the largest-selling, single-dose antibiotic in its class. The first FDA-approved fluoroquinolone antimicrobial for use against bovine respiratory disease, Baytril 100 is a proven and effective management tool. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Extra-label use of this product in food-producing animals is prohibited. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter. The effects of enrofloxacin on cattle or swine reproductive performance, pregnancy and lactation have not been adequately determined. Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose. The clinical significance of in vitro data has not been determined. For more information about Baytril 100, call Bayer Veterinary Services at 1-800-422-9874, visit www.Baytril100.com, or contact your veterinarian. About Bayer Animal Health Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. With sales of EUR 956 million (2007) the Animal Health Division is one of the world’s leading manufacturers of veterinary drugs. The division manufactures and markets approximately 100 different veterinary drugs and care products for food-supplying animals and companion animals (dogs, cats, horses). Footnotes: 1. Blondeau, JM; Borsos, S; Blondeau, LD; Blondeau, BJ; Hesje, C: The killing of clinical isolates of Mannheimia haemolytica (MH) by enrofloxacin (ENR) using minimum inhibitory and mutant prevention drug concentrations and over a range of bacterial inocula. In: ASM Conference on Pasteurellaceae; 2005 October 23-26; Kohala Coast, Big Island, Hawaii: American Society of Microbiology; 2005. Abstract B12. |